-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 3, Amgen’s 2021Q2 financial report announced that the company has stopped recruiting for the AMG 427 Phase I clinical study
In an e-mail statement, Amgen stated: "As observed in other bispecific drug studies, we encountered cytokine release syndrome in the phase I study of AMG 427.
In addition to AMG 427, Amgen also reported the "bad news" of three other CD3 double antibodies in the 2020 performance report released in February this year, specifically: 1) BCMA target for the treatment of relapsed or refractory multiple myeloma Temporary suspension of phase I trial recruitment to BiTE molecule AMG 701 due to safety issues (cytokine release syndrome); 2) Clinical development of BiTE molecule AMG 673 targeting CD33 has been suspended; 3) EGFR variant III for the treatment of glioblastoma The clinical development of the targeting BiTE molecule AMG 596 was terminated (the reason is to consider the priority of the investment portfolio)
The "good news" is that in the 2021Q2 financial report, Amgen stated that the BCMxCD3 bispecific antibody AMG 701 has resumed recruitment of patients with relapsed or refractory multiple myeloma
Bispecific antibodies have become a rising star in the field of antibodies
Up to now, the US FDA has approved 3 dual-antibody drugs for the market.
As a pioneer company in the field of bi-antis, Amgen has been seeking new breakthroughs in recent years
Through this acquisition, Amgen will also obtain Teneobio's bispecific T cell adapter molecule TNB-585 (a PSMAxCD3 bispecific antibody), which is currently in phase I clinical development for the treatment of metastatic castration Resistant prostate cancer (mCRPC)
Reference materials:
1#Amgen Reports Second Quarter 2021 Financial Results (Source: Amgen)
2#Amgen Reports Fourth Quarter And Full Year 2020 Financial Results (Source: Amgen)
3#Another one BiTEs the dust as Amgenpauses enrollment for phase 1 bispecific trial (Source: FierceBiotech) 4#2.
